{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-078226","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.619757+00:00","generated_at":"2026-06-04T07:07:48.974276+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galera Therapeutics receives Nasdaq delisting notices; plans to appeal","bullets":["March 21 notice: failed to meet $50M MVLS and $1.00 bid price for 30 consecutive days.","March 26 notice: failed to meet $15M market value of publicly held shares requirement.","Company will request hearings by March 28 and April 2 deadlines; stay pending outcome.","May request transfer to Nasdaq Capital Market; no guarantee of approval or continued listing.","Common stock (GRTX) expected to remain listed at least until Panel decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-078226","json":"https://secwatch.observer/filing/0001193125-24-078226.json","markdown":"https://secwatch.observer/filing/0001193125-24-078226.md","text":"https://secwatch.observer/filing/0001193125-24-078226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524078226/0001193125-24-078226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524078226/d797057d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:07:48.974276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"844b98de1bb7e5af800b7c898f1d4d272a297e93","claim":"Galera Therapeutics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).","evidence_excerpt":"March 26, 2024, the Company received a letter from the Staff indicating that the Company has not regained compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”), and that, unless the Company requests a hearing before a Panel to appeal Nasdaq’s delisting determination by 4:00 p.m. Eastern Time on April 2, 2024, trading of the Company’s common stock will be suspended at the opening of business on April 3, 2024, and the C","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524078226/0001193125-24-078226-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5450(b)(2)(A), 5450(b)(2)(C)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}